The Basic Principles of Chimeric Antigen Receptor Design

Overview

Journal Cancer Discov

Specialty Oncology

Date 2013 Apr 4

PMID 23550147

Citations 745

Authors

Michel Sadelain

Renier Brentjens

Isabelle Riviere

Affiliations

Soon will be listed here.

Abstract

Unlabelled: Chimeric antigen receptors (CAR) are recombinant receptors that provide both antigen-binding and T-cell-activating functions. A multitude of CARs has been reported over the past decade, targeting an array of cell surface tumor antigens. Their biologic functions have dramatically changed following the introduction of tripartite receptors comprising a costimulatory domain, termed second-generation CARs. These have recently shown clinical benefit in patients treated with CD19-targeted autologous T cells. CARs may be combined with costimulatory ligands, chimeric costimulatory receptors, or cytokines to further enhance T-cell potency, specificity, and safety. CARs represent a new class of drugs with exciting potential for cancer immunotherapy.

Significance: CARs are a new class of drugs with great potential for cancer immunotherapy. Upon their expression in T lymphocytes, CARs direct potent, targeted immune responses that have recently shown encouraging clinical outcomes in a subset of patients with B-cell malignancies. This review focuses on the design of CARs, including the requirements for optimal antigen recognition and different modalities to provide costimulatory support to targeted T cells, which include the use of second- and third generation CARs, costimulatory ligands, chimeric costimulatory receptors, and cytokines.

Citing Articles

Strategies to Overcome Antigen Heterogeneity in CAR-T Cell Therapy.

Zhang B, Wu J, Jiang H, Zhou M Cells. 2025; 14(5).

PMID: 40072049 PMC: 11899321. DOI: 10.3390/cells14050320.

Multidimensional applications of prussian blue-based nanoparticles in cancer immunotherapy.

Zhang J, Wang F, Sun Z, Ye J, Chu H J Nanobiotechnology. 2025; 23(1):161.

PMID: 40033359 PMC: 11874808. DOI: 10.1186/s12951-025-03236-x.

Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy.

De Lucia A, Mazzotti L, Gaimari A, Zurlo M, Maltoni R, Cerchione C Front Immunol. 2025; 16:1515748.

PMID: 39995659 PMC: 11847692. DOI: 10.3389/fimmu.2025.1515748.

Tumor microenvironment as a novel therapeutic target for lymphoid leukemias.

Mousavi S, Nouri S, Sadeghipour A, Atashi A Ann Hematol. 2025; .

PMID: 39994019 DOI: 10.1007/s00277-025-06237-w.

Leveraging Vector-Based Gene Disruptions to Enhance CAR T-Cell Effectiveness.

Oliveira B, Bari S, Melenhorst J Cancers (Basel). 2025; 17(3).

PMID: 39941752 PMC: 11815729. DOI: 10.3390/cancers17030383.

References

Milone M, Fish J, Carpenito C, Carroll R, Binder G, Teachey D . Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009; 17(8):1453-64. PMC: 2805264. DOI: 10.1038/mt.2009.83. View

Brentjens R, Latouche J, Santos E, Marti F, Gong M, Lyddane C . Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med. 2003; 9(3):279-86. DOI: 10.1038/nm827. View

Pule M, Straathof K, Dotti G, Heslop H, Rooney C, Brenner M . A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 2005; 12(5):933-41. DOI: 10.1016/j.ymthe.2005.04.016. View

Lee J, Hayman E, Pegram H, Santos E, Heller G, Sadelain M . In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer Res. 2011; 71(8):2871-81. PMC: 3094720. DOI: 10.1158/0008-5472.CAN-10-0552. View

Di Stasi A, Tey S, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C . Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011; 365(18):1673-83. PMC: 3236370. DOI: 10.1056/NEJMoa1106152. View

Stewart-Jones G, Wadle A, Hombach A, Shenderov E, Held G, Fischer E . Rational development of high-affinity T-cell receptor-like antibodies. Proc Natl Acad Sci U S A. 2009; 106(14):5784-8. PMC: 2667008. DOI: 10.1073/pnas.0901425106. View

Brentjens R, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K . Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res. 2007; 13(18 Pt 1):5426-35. DOI: 10.1158/1078-0432.CCR-07-0674. View

Ponomarev V, Doubrovin M, Lyddane C, Beresten T, Balatoni J, Bornman W . Imaging TCR-dependent NFAT-mediated T-cell activation with positron emission tomography in vivo. Neoplasia. 2002; 3(6):480-8. PMC: 1506564. DOI: 10.1038/sj.neo.7900204. View

Recchia A, Bonini C, Magnani Z, Urbinati F, Sartori D, Muraro S . Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. Proc Natl Acad Sci U S A. 2006; 103(5):1457-62. PMC: 1360534. DOI: 10.1073/pnas.0507496103. View

10.

Sadelain M, Riviere I, Brentjens R . Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer. 2003; 3(1):35-45. DOI: 10.1038/nrc971. View

11.

Stone J, Chervin A, Kranz D . T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity. Immunology. 2009; 126(2):165-76. PMC: 2632691. DOI: 10.1111/j.1365-2567.2008.03015.x. View

12.

Letourneur F, Klausner R . T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins. Proc Natl Acad Sci U S A. 1991; 88(20):8905-9. PMC: 52619. DOI: 10.1073/pnas.88.20.8905. View

13.

Li Y, Hayakawa K, Hardy R . The regulated expression of B lineage associated genes during B cell differentiation in bone marrow and fetal liver. J Exp Med. 1993; 178(3):951-60. PMC: 2191150. DOI: 10.1084/jem.178.3.951. View

14.

Romeo C, Seed B . Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell. 1991; 64(5):1037-46. DOI: 10.1016/0092-8674(91)90327-u. View

15.

Heslop H, Slobod K, Pule M, Hale G, Rousseau A, Smith C . Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2009; 115(5):925-35. PMC: 2817637. DOI: 10.1182/blood-2009-08-239186. View

16.

Denkberg G, Reiter Y . Recombinant antibodies with T-cell receptor-like specificity: novel tools to study MHC class I presentation. Autoimmun Rev. 2006; 5(4):252-7. DOI: 10.1016/j.autrev.2005.07.004. View

17.

Zakrzewski J, Suh D, Markley J, Smith O, King C, Goldberg G . Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. Nat Biotechnol. 2008; 26(4):453-61. PMC: 2731996. DOI: 10.1038/nbt1395. View

18.

Kowolik C, Topp M, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N . CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. 2006; 66(22):10995-1004. DOI: 10.1158/0008-5472.CAN-06-0160. View

19.

Stephan M, Ponomarev V, Brentjens R, Chang A, Dobrenkov K, Heller G . T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med. 2007; 13(12):1440-9. DOI: 10.1038/nm1676. View

20.

Hudecek M, Schmitt T, Baskar S, Lupo-Stanghellini M, Nishida T, Yamamoto T . The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood. 2010; 116(22):4532-41. PMC: 2996114. DOI: 10.1182/blood-2010-05-283309. View